[
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "Clinical Trial Watch is an automated monitoring system designed to track changes in clinical trials related to selected therapeutic targets (e.g., CCR8, TIGIT, IgE). By leveraging the ClinicalTrials.gov API v2, this project provides researchers and clinicians with a clear, up-to-date view of the competitive landscape."
  },
  {
    "objectID": "about.html#project-overview",
    "href": "about.html#project-overview",
    "title": "About",
    "section": "",
    "text": "Clinical Trial Watch is an automated monitoring system designed to track changes in clinical trials related to selected therapeutic targets (e.g., CCR8, TIGIT, IgE). By leveraging the ClinicalTrials.gov API v2, this project provides researchers and clinicians with a clear, up-to-date view of the competitive landscape."
  },
  {
    "objectID": "about.html#key-features",
    "href": "about.html#key-features",
    "title": "About",
    "section": "Key Features",
    "text": "Key Features\n\nAutomated Monitoring: Daily updates on the status and key parameters of clinical trials for multiple targets.\nChange Detection: Intelligent diffing engine that highlights meaningful changes in recruitment status, phase, and completion dates.\nData Insights: Interactive visualizations to help understand clinical trial trends and distributions for each target.\nOpen Data: All consolidated raw data is available for download as a CSV for deeper analysis."
  },
  {
    "objectID": "about.html#how-it-works",
    "href": "about.html#how-it-works",
    "title": "About",
    "section": "How it Works",
    "text": "How it Works\n\nDaily Watch: A GitHub Actions workflow runs every 24 hours to fetch the latest data for all NCT IDs listed in trials.yaml.\nAnalysis: The src/main.py script compares current data with previous snapshots to identify any changes.\nReport Generation: Updates are logged in the history.qmd page, and the dashboard is refreshed with the latest summary stats.\nPublishing: The updated Quarto website is automatically published to GitHub Pages."
  },
  {
    "objectID": "about.html#data-source",
    "href": "about.html#data-source",
    "title": "About",
    "section": "Data Source",
    "text": "Data Source\nAll data is sourced from ClinicalTrials.gov via their official API.\n\nThis project is built using Python, Quarto, and GitHub Actions."
  },
  {
    "objectID": "targets/tigit.html",
    "href": "targets/tigit.html",
    "title": "TIGIT",
    "section": "",
    "text": "Note\n\n\n\nTIGIT íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§"
  },
  {
    "objectID": "targets/tigit.html#visual-summary",
    "href": "targets/tigit.html#visual-summary",
    "title": "TIGIT",
    "section": "Visual Summary",
    "text": "Visual Summary\n\nStatus & PhaseTop Sponsors"
  },
  {
    "objectID": "targets/tigit.html#change-history",
    "href": "targets/tigit.html#change-history",
    "title": "TIGIT",
    "section": "Change History",
    "text": "Change History\n\nTarget MilestonesTrial Changes\n\n\nDate: 2026-02-16 21:08:12\nChanges detected in 3 trials: NCT05805501, NCT05123482, NCT06627647\n\nDate: 2026-02-12 14:01:41\nChanges detected in 3 trials: NCT05574335, NCT07221253, NCT06989112\n\nDate: 2026-02-10 07:03:54\nChanges detected in 2 trials: NCT07115043, NCT07098338\n\nDate: 2026-02-05 15:27:28\nInitial data collection: 133 trials found.\n\n\n\n\nNCT05805501\nDate: 2026-02-16 21:08:09\nField statusModule.statusVerifiedDate changed from 2025-11 to 2026-02 Field statusModule.primaryCompletionDateStruct.date changed from 2026-07-31 to 2026-10-31 Field statusModule.completionDateStruct.date changed from 2026-07-31 to 2026-10-31 Field statusModule.lastUpdateSubmitDate changed from 2025-11-12 to 2026-02-10 Field statusModule.lastUpdatePostDateStruct.date changed from 2025-11-13 to 2026-02-12\n\n\n\nNCT07115043\nDate: 2026-02-10 07:03:45\nField statusModule.statusVerifiedDate changed from 2025-12 to 2026-02 Field statusModule.lastUpdateSubmitDate changed from 2025-12-18 to 2026-02-04 Field statusModule.lastUpdatePostDateStruct.date changed from 2025-12-19 to 2026-02-05 Field contactsLocationsModule.locations.[1]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[3]status changed from NOT_YET_RECRUITING to RECRUITING\n\n\n\nNCT05123482\nDate: 2026-02-16 21:08:10\nField statusModule.statusVerifiedDate changed from 2025-11 to 2026-02 Field statusModule.lastUpdateSubmitDate changed from 2025-12-02 to 2026-02-11 Field statusModule.lastUpdatePostDateStruct.date changed from 2025-12-08 to 2026-02-13 Field contactsLocationsModule.locations.[0]status changed from RECRUITING to COMPLETED Field contactsLocationsModule.locations.[1]status changed from RECRUITING to COMPLETED Field contactsLocationsModule.locations.[18]status changed from WITHDRAWN to NOT_YET_RECRUITING Field contactsLocationsModule.locations.[18]city changed from South Brisbane to Taichung Field contactsLocationsModule.locations.[18]zip changed from 4101 to 40705 Field contactsLocationsModule.locations.[18]country changed from Australia to Taiwan Field contactsLocationsModule.locations.[18]geoPoint.lat changed from -27.48034 to 24.1469 Field contactsLocationsModule.locations.[18]geoPoint.lon changed from 153.02049 to 120.6839\n\n\n\nNCT05574335\nDate: 2026-02-12 14:01:39\nField statusModule.statusVerifiedDate changed from 2026-01 to 2026-02 Field statusModule.lastUpdateSubmitDate changed from 2026-01-05 to 2026-02-10 Field statusModule.lastUpdatePostDateStruct.date changed from 2026-01-06 to 2026-02-11\n\n\n\nNCT07098338\nDate: 2026-02-10 07:03:50\nField statusModule.statusVerifiedDate changed from 2025-09 to 2026-01 Field statusModule.primaryCompletionDateStruct.date changed from 2027-03-21 to 2029-04-06 Field statusModule.lastUpdateSubmitDate changed from 2025-09-25 to 2026-02-03 Field statusModule.lastUpdatePostDateStruct.date changed from 2025-09-30 to 2026-02-05 Field descriptionModule.detailedDescription changed from `The master protocol will include 3 sub-studies, each focused on a specific disease population.\n\nSub-study 1 will investigate rilvegostomigÂ± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 â‰¥50%.\nSub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.\nSub-study 3 will investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2L AGA+\n\nEach sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).toThe master protocol will include 3 sub-studies, each focused on a specific disease population.\n\nSub-study 1 will investigate rilvegostomigÂ± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 â‰¥50%.\nSub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.\nSub-study 3 will investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2/3L AGA+\n\nEach sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).FieldoutcomesModule.primaryOutcomes.[1]descriptionchanged fromORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response), determined by the Investigator at local site per RECIST 1.1toORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response) per RECIST 1.1FieldoutcomesModule.secondaryOutcomes.[2]descriptionchanged fromPFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1 as assessed by Investigator.toPFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1.FieldcontactsLocationsModule.locations.[10]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[11]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[12]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[14]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[16]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[17]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[19]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[26]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[28]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[29]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[32]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[33]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[34]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[36]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[37]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[38]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[40]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[41]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[42]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[43]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[44]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[46]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[48]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[50]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldcontactsLocationsModule.locations.[51]statuschanged fromNOT_YET_RECRUITINGtoRECRUITINGFieldarmsInterventionsModule.armGroups.[0]changed from{â€˜labelâ€™: â€˜Sub-study 1, investigate rilvegostomigÂ± ramucirumab in 1L non-AGA NSCLC with PD-L1 â‰¥50%â€™, â€˜typeâ€™: â€˜EXPERIMENTALâ€™, â€˜descriptionâ€™: â€˜Participants will receive rilvegostomig Â± ramucirumab until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterionâ€™, â€˜interventionNamesâ€™: [â€˜Drug: Rilvegostomigâ€™, â€˜Drug: Ramucirumabâ€™]}to{â€˜labelâ€™: â€˜Sub-study 1, investigate rilvegostomigÂ± ramucirumab in 1L non-AGA NSCLC with PD-L1 â‰¥50%â€™, â€˜typeâ€™: â€˜EXPERIMENTALâ€™, â€˜descriptionâ€™: â€˜Participants will receive rilvegostomig Â± ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterionâ€™, â€˜interventionNamesâ€™: [â€˜Drug: Rilvegostomigâ€™, â€˜Drug: Ramucirumabâ€™]}FieldarmsInterventionsModule.interventions.[2]changed from{â€˜typeâ€™: â€˜DRUGâ€™, â€˜nameâ€™: â€˜Dato-DXdâ€™, â€˜descriptionâ€™: â€˜Dato-DXd will be administered as IV infusion.â€™, â€˜armGroupLabelsâ€™: [â€˜Sub-study 3, investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2L AGA+ NSCLCâ€™], â€˜otherNamesâ€™: [â€˜DS-1062â€™]}to{â€˜typeâ€™: â€˜DRUGâ€™, â€˜nameâ€™: â€˜Dato-DXdâ€™, â€˜descriptionâ€™: â€˜Dato-DXd will be administered as IV infusion.â€™, â€˜armGroupLabelsâ€™: [â€˜Sub-study 3, investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2/3L AGA+ NSCLCâ€™], â€˜otherNamesâ€™: [â€˜DS-1062â€™]}FieldarmsInterventionsModule.interventions.[0]changed from{â€˜typeâ€™: â€˜DRUGâ€™, â€˜nameâ€™: â€˜Rilvegostomigâ€™, â€˜descriptionâ€™: â€˜Rilvegostomig will be administered as IV infusion.â€™, â€˜armGroupLabelsâ€™: [â€˜Sub-study 1, investigate rilvegostomigÂ± ramucirumab in 1L non-AGA NSCLC with PD-L1 â‰¥50%â€™, â€˜Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%â€™, â€˜Sub-study 3, investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2L AGA+ NSCLCâ€™], â€˜otherNamesâ€™: [â€˜AZD2936â€™]}to{â€˜typeâ€™: â€˜DRUGâ€™, â€˜nameâ€™: â€˜Rilvegostomigâ€™, â€˜descriptionâ€™: â€˜Rilvegostomig will be administered as IV infusion.â€™, â€˜armGroupLabelsâ€™: [â€˜Sub-study 1, investigate rilvegostomigÂ± ramucirumab in 1L non-AGA NSCLC with PD-L1 â‰¥50%â€™, â€˜Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%â€™, â€˜Sub-study 3, investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2/3L AGA+ NSCLCâ€™], â€˜otherNamesâ€™: [â€˜AZD2936â€™]}FieldarmsInterventionsModule.armGroups.[2]changed from{â€˜labelâ€™: â€˜Sub-study 3, investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2L AGA+ NSCLCâ€™, â€˜typeâ€™: â€˜EXPERIMENTALâ€™, â€˜descriptionâ€™: â€˜Participants will receive Dato-DXd + ramucirumab Â± rilvegostomig until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterionâ€™, â€˜interventionNamesâ€™: [â€˜Drug: Rilvegostomigâ€™, â€˜Drug: Ramucirumabâ€™, â€˜Drug: Dato-DXdâ€™]}to{â€˜labelâ€™: â€˜Sub-study 3, investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2/3L AGA+ NSCLCâ€™, â€˜typeâ€™: â€˜EXPERIMENTALâ€™, â€˜descriptionâ€™: â€˜Participants will receive Dato-DXd + ramucirumab Â± rilvegostomig until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterionâ€™, â€˜interventionNamesâ€™: [â€˜Drug: Rilvegostomigâ€™, â€˜Drug: Ramucirumabâ€™, â€˜Drug: Dato-DXdâ€™]}FieldarmsInterventionsModule.armGroups.[1]changed from{â€˜labelâ€™: â€˜Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%â€™, â€˜typeâ€™: â€˜EXPERIMENTALâ€™, â€˜descriptionâ€™: â€˜Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterionâ€™, â€˜interventionNamesâ€™: [â€˜Drug: Rilvegostomigâ€™, â€˜Drug: Ramucirumabâ€™]}to{â€˜labelâ€™: â€˜Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%â€™, â€˜typeâ€™: â€˜EXPERIMENTALâ€™, â€˜descriptionâ€™: â€˜Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterionâ€™, â€˜interventionNamesâ€™: [â€˜Drug: Rilvegostomigâ€™, â€˜Drug: Ramucirumabâ€™]}FieldarmsInterventionsModule.interventions.[1]changed from{â€˜typeâ€™: â€˜DRUGâ€™, â€˜nameâ€™: â€˜Ramucirumabâ€™, â€˜descriptionâ€™: â€˜Ramucirumab will be administered as IV infusion.â€™, â€˜armGroupLabelsâ€™: [â€˜Sub-study 1, investigate rilvegostomigÂ± ramucirumab in 1L non-AGA NSCLC with PD-L1 â‰¥50%â€™, â€˜Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%â€™, â€˜Sub-study 3, investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2L AGA+ NSCLCâ€™], â€˜otherNamesâ€™: [â€˜Cyramzaâ€™]}to{â€˜typeâ€™: â€˜DRUGâ€™, â€˜nameâ€™: â€˜Ramucirumabâ€™, â€˜descriptionâ€™: â€˜Ramucirumab will be administered as IV infusion.â€™, â€˜armGroupLabelsâ€™: [â€˜Sub-study 1, investigate rilvegostomigÂ± ramucirumab in 1L non-AGA NSCLC with PD-L1 â‰¥50%â€™, â€˜Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%â€™, â€˜Sub-study 3, investigate Dato-DXd + ramucirumab Â± rilvegostomig in 2/3L AGA+ NSCLCâ€™], â€˜otherNamesâ€™: [â€˜Cyramzaâ€™]}`\n\n\n\nNCT07221253\nDate: 2026-02-12 14:01:40\nField statusModule.statusVerifiedDate changed from 2025-12 to 2026-02 Field statusModule.lastUpdateSubmitDate changed from 2026-01-07 to 2026-02-09 Field statusModule.lastUpdatePostDateStruct.date changed from 2026-01-08 to 2026-02-10 Field contactsLocationsModule.locations.[32]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[39]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[40]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[43]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[58]status changed from NOT_YET_RECRUITING to SUSPENDED Field contactsLocationsModule.locations.[89]city changed from Lichtenberg to Berlin Field contactsLocationsModule.locations.[89]geoPoint.lat changed from 52.51395 to 52.52437 Field contactsLocationsModule.locations.[89]geoPoint.lon changed from 13.49975 to 13.41053 Field contactsLocationsModule.locations.[103]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[131]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[138]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[141]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[143]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[145]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[147]status changed from NOT_YET_RECRUITING to RECRUITING\n\n\n\nNCT06989112\nDate: 2026-02-12 14:01:41\nField statusModule.statusVerifiedDate changed from 2026-01 to 2026-02 Field statusModule.lastUpdateSubmitDate changed from 2026-01-14 to 2026-02-09 Field statusModule.lastUpdatePostDateStruct.date changed from 2026-01-15 to 2026-02-10 Field contactsLocationsModule.locations.[11]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[46]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[57]zip changed from 53705 to 53792 Field contactsLocationsModule.locations.[70]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[76]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[78]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[79]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[121]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[149]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[182]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[190]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[223]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[245]status changed from NOT_YET_RECRUITING to RECRUITING\n\n\n\nNCT06627647\nDate: 2026-02-16 21:08:12\nField statusModule.statusVerifiedDate changed from 2025-12 to 2026-02 Field statusModule.lastUpdateSubmitDate changed from 2025-12-19 to 2026-02-11 Field statusModule.lastUpdatePostDateStruct.date changed from 2025-12-22 to 2026-02-12 Field contactsLocationsModule.locations.[16]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[23]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[179]status changed from NOT_YET_RECRUITING to WITHDRAWN Field contactsLocationsModule.locations.[183]status changed from RECRUITING to WITHDRAWN Field contactsLocationsModule.locations.[196]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[202]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[232]status changed from NOT_YET_RECRUITING to SUSPENDED\n\n\n\n\n\n\nğŸ“¥ Download Full Data (CSV) ğŸ“¥ Download Status Summary (CSV)"
  },
  {
    "objectID": "targets/tigit.html#monitoring-status",
    "href": "targets/tigit.html#monitoring-status",
    "title": "TIGIT",
    "section": "Monitoring Status",
    "text": "Monitoring Status\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04995523\nAstraZeneca\nğŸŸ¢ No Change\nRECRUITING\nNon-Small-Cell Lung Carcinoma\nPHASE1, PHASE2\n2021-09-14\n2028-03-16\n210\n2025-11-21\n\n\nNCT04150965\nMultiple Myeloma Research Consortium\nğŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nPHASE1, PHASE2\n2020-07-10\n2024-08-30\n14\n2025-02-12\n\n\nNCT05483400\nUniversity Medical Center Groningen\nğŸŸ¢ No Change\nRECRUITING\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\nPHASE2\n2023-10-18\n2027-09\n97\n2025-03-28\n\n\nNCT05607563\nBiotheus Inc.\nğŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumor\nPHASE1\n2022-11-21\n2023-12\n54\n2023-02-07\n\n\nNCT05394168\nShanghai Henlius Biotech\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced/Metastatic Solid Tumors\nPHASE1\n2022-12-09\n2025-03-04\n12\n2024-03-28\n\n\nNCT04500678\nUniversity of Hawaii\nğŸŸ¢ No Change\nUNKNOWN\nHIV/AIDS\nPHASE2, PHASE3\n2019-02-01\n2022-12-31\n38\n2020-08-04\n\n\nNCT07171307\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nConjunctivitis, Allergic\nN/A\n2026-01-01\n2026-09\n60\n2025-09-15\n\n\nNCT03119428\nOncoMed Pharmaceuticals, Inc.\nğŸŸ¢ No Change\nTERMINATED\nLocally Advanced Cancer, Metastatic Cancer\nPHASE1\n2017-05-02\n2019-05-15\n33\n2020-08-10\n\n\nNCT04818619\nAssiut University\nğŸŸ¢ No Change\nUNKNOWN\nChronic Myeloid Leukemia\nN/A\n2021-04\n2022-12\n65\n2021-03-25\n\n\nNCT05390528\nShanghai Henlius Biotech\nğŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors, Lymphoma, Metastatic Tumors\nPHASE1, PHASE2\n2022-06-20\n2024-12-30\n30\n2023-08-07\n\n\nNCT06250036\nRoyal Marsden NHS Foundation Trust\nğŸŸ¢ No Change\nRECRUITING\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer\nPHASE2\n2025-02-20\n2031-09-01\n50\n2025-08-19\n\n\nNCT05023109\nShanghai Zhongshan Hospital\nğŸŸ¢ No Change\nUNKNOWN\nBiliary Tract Carcinoma\nPHASE2\n2021-02-01\n2024-12-01\n45\n2023-08-12\n\n\nNCT05061628\nShanghai Junshi Bioscience Co., Ltd.\nğŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors\nPHASE1\n2021-04-21\n2024-09-30\n176\n2021-09-21\n\n\nNCT05102214\nShanghai Henlius Biotech\nğŸŸ¢ No Change\nUNKNOWN\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2022-05-03\n2024-02\n150\n2023-08-07\n\n\nNCT05653284\nAkeso\nğŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignant Tumors\nPHASE1\n2023-02-09\n2024-05-30\n19\n2024-08-11\n\n\nNCT05537051\nBiotheus Inc.\nğŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumours\nPHASE1\n2023-10-30\n2025-12-31\n30\n2023-02-07\n\n\nNCT04656535\nYale University\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nEARLY_PHASE1\n2021-04-21\n2026-12-31\n46\n2026-01-06\n\n\nNCT05019677\nFudan University\nğŸŸ¢ No Change\nWITHDRAWN\nIntrahepatic Cholangiocarcinoma\nPHASE2\n2021-09-01\n2024-12-01\n0\n2022-03-22\n\n\nNCT05130177\nDiwakar Davar\nğŸŸ¢ No Change\nRECRUITING\nMelanoma\nPHASE2\n2022-03-16\n2031-01\n26\n2025-05-02\n\n\nNCT04047862\nBeiGene\nğŸŸ¢ No Change\nCOMPLETED\nLocally Advanced and Metastatic Solid Tumors\nPHASE1\n2019-08-15\n2024-08-07\n446\n2025-08-04\n\n\nNCT05706207\nHuabo Biopharm Co., Ltd.\nğŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-12-21\n2023-09-30\n36\n2023-01-20\n\n\nNCT05394337\nM.D.Â Anderson Cancer Center\nğŸŸ¢ No Change\nRECRUITING\nMetastatic Malignancy\nPHASE1, PHASE2\n2023-02-23\n2025-12-31\n10\n2025-10-07\n\n\nNCT06773507\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPHASE1\n2025-05-12\n2027-06\n80\n2025-07-07\n\n\nNCT05253105\nShanghai Junshi Bioscience Co., Ltd.\nğŸŸ¢ No Change\nWITHDRAWN\nPreviously Treated, Advanced, Malignancies\nPHASE1\n2022-03-15\n2027-01\n0\n2022-05-24\n\n\nNCT05060432\niTeos Belgium SA\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nPHASE1, PHASE2\n2021-09-06\n2025-07\n153\n2024-06-19\n\n\nNCT05294952\nAssiut University\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nPre-Eclampsia\nPHASE4\n2025-01-01\n2025-11-04\n82\n2024-02-01\n\n\nNCT06349980\nShanghai Henlius Biotech\nğŸŸ¢ No Change\nRECRUITING\nCarcinoma, Hepatocellular\nPHASE2\n2024-08-05\n2027-02-10\n117\n2024-12-15\n\n\nNCT06713798\nGustave Roussy, Cancer Campus, Grand Paris\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\nPHASE2\n2025-07\n2030-01\n115\n2025-06-23\n\n\nNCT04270942\nProvention Bio, a Sanofi Company\nğŸŸ¢ No Change\nCOMPLETED\nDiabetes Mellitus, Type 1\nPHASE2\n2020-02-26\n2024-01-22\n6\n2025-01-20\n\n\nNCT06754501\nM.D.Â Anderson Cancer Center\nğŸŸ¢ No Change\nRECRUITING\nCancer\nPHASE2\n2025-04-11\n2029-07-01\n35\n2025-10-01\n\n\nNCT05757492\nCoherus Oncology, Inc.\nğŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nPHASE1\n2023-04-26\n2024-07-31\n22\n2025-04-30\n\n\nNCT04952597\nBeiGene\nğŸŸ¢ No Change\nCOMPLETED\nLimited Stage Small Cell Lung Cancer\nPHASE2\n2021-07-15\n2023-07-26\n126\n2024-10-23\n\n\nNCT05805501\nHoffmann-La Roche\nğŸ”´ Changed\nACTIVE_NOT_RECRUITING\nRenal Cell Carcinoma\nPHASE2\n2023-04-21\n2026-10-31\n199\n2026-02-10\n\n\nNCT04672356\nInnovent Biologics (Suzhou) Co.Â Ltd.\nğŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-01-25\n2023-06-01\n19\n2023-06-18\n\n\nNCT04672369\nInnovent Biologics (Suzhou) Co.Â Ltd.\nğŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-06-06\n2023-06-01\n42\n2023-06-18\n\n\nNCT05009069\nHoffmann-La Roche\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRectal Neoplasms, Rectal Cancer\nPHASE2\n2022-03-18\n2026-11-06\n58\n2026-01-16\n\n\nNCT07337447\nHospices Civils de Lyon\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nCarcinoma, Neuroendocrine\nPHASE2\n2026-04\n2030-04\n122\n2026-01-07\n\n\nNCT03447678\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\nğŸŸ¢ No Change\nUNKNOWN\nNon Small Cell Lung Cancer (NSCLC)\nPHASE2\n2018-05-23\n2022-05-31\n65\n2021-06-08\n\n\nNCT04353830\nInnovent Biologics (Suzhou) Co.Â Ltd.\nğŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignancies\nPHASE1\n2020-05-22\n2022-05-11\n34\n2023-02-28\n\n\nNCT04354246\nCompugen Ltd\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC\nPHASE1\n2020-03-31\n2025-12-30\n110\n2025-05-18\n\n\nNCT04933227\nHoffmann-La Roche\nğŸŸ¢ No Change\nTERMINATED\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\nPHASE2\n2021-08-06\n2023-11-17\n29\n2024-11-11\n\n\nNCT05414032\nUniversity Health Network, Toronto\nğŸŸ¢ No Change\nRECRUITING\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\nPHASE2\n2023-07-12\n2026-07\n200\n2025-03-25\n\n\nNCT06777628\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\nğŸŸ¢ No Change\nRECRUITING\nLiver Cancer, Adult\nN/A\n2024-09-15\n2028-10-15\n100\n2025-01-14\n\n\nNCT06003621\nOmico\nğŸŸ¢ No Change\nRECRUITING\nSolid Tumor, Adult\nPHASE2\n2023-12-15\n2028-11-01\n96\n2024-11-13\n\n\nNCT06773481\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nğŸŸ¢ No Change\nRECRUITING\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV\nPHASE1\n2025-04-07\n2026-12\n40\n2025-07-07\n\n\nNCT05568095\nArcus Biosciences, Inc.\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nPHASE3\n2022-11-21\n2026-06\n1040\n2026-01-30\n\n\nNCT03486119\nYonsei University\nğŸŸ¢ No Change\nCOMPLETED\nNon -Small Cell Lung Cancer\nN/A\n2018-02-05\n2020-07-07\n60\n2020-10-14\n\n\nNCT03708224\nAlain Algazi\nğŸŸ¢ No Change\nRECRUITING\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nPHASE2\n2019-03-08\n2028-06-30\n55\n2025-01-24\n\n\nNCT03652402\nAssistance Publique - HÃ´pitaux de Paris\nğŸŸ¢ No Change\nCOMPLETED\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nN/A\n2018-11-27\n2021-10-28\n558\n2024-06-04\n\n\nNCT05120375\nBio-Thera Solutions\nğŸŸ¢ No Change\nTERMINATED\nSolid Tumor\nPHASE1\n2022-02-17\n2023-04-07\n5\n2023-10-08\n\n\nNCT04570839\nCompugen Ltd\nğŸŸ¢ No Change\nCOMPLETED\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nPHASE1, PHASE2\n2020-08-31\n2024-05-15\n48\n2024-07-17\n\n\nNCT05327530\nEMD Serono Research & Development Institute, Inc.\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nLocally Advanced or Metastatic Urothelial Carcinoma\nPHASE2\n2022-08-17\n2026-06-25\n256\n2026-01-23\n\n\nNCT05520294\nUniversity of Colorado, Denver\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nN/A\n2022-09-01\n2024-08-31\n90\n2024-04-15\n\n\nNCT05417321\nShanghai Huaota Biopharmaceutical Co., Ltd.\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor, NSCLC\nPHASE1, PHASE2\n2022-08-25\n2025-08-01\n80\n2025-01-02\n\n\nNCT05126537\nSoutheast University, China\nğŸŸ¢ No Change\nUNKNOWN\n28 Day Mortality\nN/A\n2022-01-01\n2022-12-31\n100\n2022-11-25\n\n\nNCT06328036\nNational Cancer Institute (NCI)\nğŸŸ¢ No Change\nWITHDRAWN\nRecurrent Glioblastoma, IDH-Wildtype\nPHASE2\n2025-04-30\n2025-07-01\n0\n2024-12-27\n\n\nNCT04736173\nArcus Biosciences, Inc.\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2021-02-08\n2027-05\n169\n2025-12-09\n\n\nNCT04262856\nArcus Biosciences, Inc.\nğŸŸ¢ No Change\nCOMPLETED\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2020-05-28\n2025-07-09\n151\n2025-08-25\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nğŸŸ¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\n2025-10-02\n\n\nNCT05289492\niTeos Therapeutics\nğŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma\nPHASE1\n2022-05-01\n2023-11-29\n16\n2024-10-23\n\n\nNCT05743504\nNational Taiwan University Hospital\nğŸŸ¢ No Change\nUNKNOWN\nLocally Advanced Esophageal Squamous Cell Carcinoma\nPHASE1, PHASE2\n2023-09-18\n2025-11-30\n32\n2024-01-31\n\n\nNCT07115043\nAstraZeneca\nğŸ”´ Changed\nRECRUITING\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma\nPHASE1, PHASE2\n2025-07-29\n2029-10-02\n60\n2026-02-04\n\n\nNCT05073484\nBio-Thera Solutions\nğŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1\n2021-10-29\n2023-03-30\n13\n2023-10-09\n\n\nNCT07376512\nCentre Georges Francois Leclerc\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nN/A\n2026-03-01\n2030-03-01\n378\n2026-01-22\n\n\nNCT05904886\nHoffmann-La Roche\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nHepatocellular Carcinoma\nPHASE3\n2023-09-14\n2026-09-01\n687\n2025-12-30\n\n\nNCT03739710\nGlaxoSmithKline\nğŸŸ¢ No Change\nCOMPLETED\nNeoplasms\nPHASE2\n2019-01-24\n2024-05-02\n175\n2025-06-13\n\n\nNCT05020912\nCase Comprehensive Cancer Center\nğŸŸ¢ No Change\nRECRUITING\nBasal Cell Carcinoma\nPHASE2\n2021-12-13\n2027-12\n28\n2025-11-25\n\n\nNCT06334406\nCentre Hospitalier Universitaire de Besancon\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nBladder Cancer\nN/A\n2024-04-02\n2026-04-02\n33\n2024-03-19\n\n\nNCT04791839\nWashington University School of Medicine\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\nPHASE2\n2021-08-04\n2030-06-30\n30\n2025-11-04\n\n\nNCT07343310\nKine Sciences Co., Ltd.\nğŸŸ¢ No Change\nCOMPLETED\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nPHASE1\n2024-08-27\n2025-04-14\n9\n2026-01-15\n\n\nNCT05123482\nAstraZeneca\nğŸ”´ Changed\nRECRUITING\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer\nPHASE1, PHASE2\n2021-10-18\n2027-09-29\n460\n2026-02-11\n\n\nNCT04682665\nUniversity of Leeds\nğŸŸ¢ No Change\nCOMPLETED\nColon Cancer Liver Metastasis\nN/A\n2021-09-16\n2024-07-31\n81\n2024-12-03\n\n\nNCT03342417\nExcellaBio LLC\nğŸŸ¢ No Change\nTERMINATED\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nPHASE2\n2018-02-14\n2019-05-29\n5\n2021-11-05\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT03628677\nArcus Biosciences, Inc.\nğŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Unspecified, Adult\nPHASE1\n2018-09-12\n2025-01-23\n75\n2025-02-03\n\n\nNCT07015164\nAssistance Publique - HÃ´pitaux de Paris\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nHIV\nN/A\n2025-06-10\n2026-09-11\n80\n2025-06-03\n\n\nNCT07161414\nAstraZeneca\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-11-25\n2029-07-24\n40\n2025-12-18\n\n\nNCT06897436\nMedical University of Lublin\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nEndometriosis\nN/A\n2025-05-01\n2029-12-31\n60\n2025-03-24\n\n\nNCT05702229\nAstraZeneca\nğŸŸ¢ No Change\nRECRUITING\nGastric Cancer\nPHASE2\n2023-01-16\n2027-09-28\n240\n2025-11-14\n\n\nNCT05633927\nHospitales Universitarios Virgen del RocÃ­o\nğŸŸ¢ No Change\nCOMPLETED\nSARS-CoV-2 RNA Vaccines, HIV Infection\nN/A\n2021-04-01\n2022-12-01\n48\n2024-10-09\n\n\nNCT05775159\nAstraZeneca\nğŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Biliary Tract Cancer\nPHASE2\n2023-04-24\n2027-10-28\n294\n2025-11-12\n\n\nNCT06338657\nUniversity of Southern California\nğŸŸ¢ No Change\nTERMINATED\nHead and Neck Squamous Cell Carcinoma\nPHASE1\n2024-04-01\n2025-09-09\n1\n2025-09-09\n\n\nNCT04624828\nIstituto Clinico Humanitas\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\nNA\n2020-10-19\n2026-07\n40\n2025-04-22\n\n\nNCT04836507\nCurocell Inc.\nğŸŸ¢ No Change\nRECRUITING\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)\nPHASE1, PHASE2\n2021-03-02\n2028-02\n91\n2021-04-29\n\n\nNCT06860815\nCity of Hope Medical Center\nğŸŸ¢ No Change\nRECRUITING\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver\nPHASE2\n2026-04-01\n2027-01-30\n11\n2026-01-27\n\n\nNCT05574335\nNational Institute of Allergy and Infectious Diseases (NIAID)\nğŸ”´ Changed\nTERMINATED\nType 1 Diabetes Mellitus\nPHASE1, PHASE2\n2023-04-26\n2025-10-20\n8\n2026-02-10\n\n\nNCT04761198\nMereo BioPharma\nğŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\nPHASE1, PHASE2\n2021-03-23\n2023-10-30\n76\n2025-03-07\n\n\nNCT06302556\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nLung Transplant Rejection\nN/A\n2024-04\n2026-02\n280\n2024-03-06\n\n\nNCT04693234\nBeiGene\nğŸŸ¢ No Change\nCOMPLETED\nCervical Cancer\nPHASE2\n2021-02-15\n2023-08-31\n178\n2025-04-09\n\n\nNCT03563716\nGenentech, Inc.\nğŸŸ¢ No Change\nCOMPLETED\nNon-small Cell Lung Cancer\nPHASE2\n2018-08-10\n2025-11-24\n135\n2025-12-30\n\n\nNCT05645692\nHoffmann-La Roche\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nUrothelial Cancer\nPHASE2\n2023-04-13\n2026-12-31\n204\n2026-01-28\n\n\nNCT05809895\nNovartis Pharmaceuticals\nğŸŸ¢ No Change\nWITHDRAWN\nTriple Negative Breast Cancer\nPHASE2\n2023-09-15\n2029-07-18\n0\n2023-07-21\n\n\nNCT07324642\nKine Sciences Co., Ltd.\nğŸŸ¢ No Change\nCOMPLETED\nHealthy Volunteers\nPHASE1\n2025-05-26\n2025-08-25\n24\n2025-12-24\n\n\nNCT03772899\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1\n2019-03-27\n2026-08\n20\n2025-03-26\n\n\nNCT04457778\nEMD Serono Research & Development Institute, Inc.\nğŸŸ¢ No Change\nCOMPLETED\nMetastatic Solid Tumors\nPHASE1\n2020-07-10\n2023-06-23\n58\n2023-12-07\n\n\nNCT04374877\nCoherus Oncology, Inc.\nğŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer\nPHASE1\n2020-04-22\n2025-06-05\n145\n2025-11-06\n\n\nNCT06346197\nCentre Leon Berard\nğŸŸ¢ No Change\nRECRUITING\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\nPHASE3\n2025-12-08\n2028-05-15\n132\n2025-12-19\n\n\nNCT05780073\nFundaciÃ³ Institut Germans Trias i Pujol\nğŸŸ¢ No Change\nCOMPLETED\nHIV Infection Primary\nPHASE2\n2023-10-16\n2025-04-01\n60\n2025-09-16\n\n\nNCT04732494\nBeiGene\nğŸŸ¢ No Change\nCOMPLETED\nEsophageal Squamous Cell Carcinoma\nPHASE2\n2021-03-31\n2023-12-26\n125\n2024-12-23\n\n\nNCT03667716\nCompugen Ltd\nğŸŸ¢ No Change\nCOMPLETED\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer\nPHASE1\n2018-09-06\n2024-01-30\n121\n2025-01-15\n\n\nNCT03661047\nMassachusetts General Hospital\nğŸŸ¢ No Change\nWITHDRAWN\nColon Cancer\nPHASE2\n2019-11-30\n2021-11-30\n0\n2021-11-10\n\n\nNCT06784947\nUniversity of Colorado, Denver\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV\nPHASE2\n2025-03-25\n2028-05\n13\n2025-10-01\n\n\nNCT07098338\nAstraZeneca\nğŸ”´ Changed\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE2\n2025-08-07\n2029-04-06\n278\n2026-02-03\n\n\nNCT06864598\nPeking University Peopleâ€™s Hospital\nğŸŸ¢ No Change\nENROLLING_BY_INVITATION\nGraft-versus-host Disease (GVHD)\nN/A\n2025-01-09\n2026-10-31\n100\n2025-03-04\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\n2025-12-13\n\n\nNCT06532539\nShandong Cancer Hospital and Institute\nğŸŸ¢ No Change\nRECRUITING\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nPHASE2\n2024-06-13\n2026-05\n30\n2024-07-29\n\n\nNCT05014815\nBeiGene\nğŸŸ¢ No Change\nCOMPLETED\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV\nPHASE2\n2021-11-16\n2024-09-04\n272\n2025-08-28\n\n\nNCT04866017\nBeiGene\nğŸŸ¢ No Change\nTERMINATED\nNon Small Cell Lung Cancer\nPHASE3\n2021-06-17\n2023-10-17\n63\n2024-10-09\n\n\nNCT04746924\nBeiGene\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon-small Cell Lung Cancer, NSCLC\nPHASE3\n2021-06-08\n2026-03-31\n662\n2025-06-23\n\n\nNCT05127824\nJodi Maranchie\nğŸŸ¢ No Change\nRECRUITING\nCarcinoma, Renal Cell\nPHASE2\n2023-07-06\n2026-12\n42\n2025-04-30\n\n\nNCT05329766\nArcus Biosciences, Inc.\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGastrointestinal Tract Malignancies\nPHASE2\n2022-06-10\n2027-06\n332\n2026-01-27\n\n\nNCT04303169\nMerck Sharp & Dohme LLC\nğŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-09-24\n146\n2025-10-23\n\n\nNCT04323202\nCase Comprehensive Cancer Center\nğŸŸ¢ No Change\nCOMPLETED\nBasal Cell Carcinoma of the Head and Neck\nPHASE1\n2020-08-04\n2025-06-25\n13\n2025-10-23\n\n\nNCT07221253\nAstraZeneca\nğŸ”´ Changed\nRECRUITING\nBiliary Tract Cancer\nPHASE3\n2025-12-04\n2029-07-04\n1100\n2026-02-09\n\n\nNCT06790706\nHospices Civils de Lyon\nğŸŸ¢ No Change\nRECRUITING\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor\nPHASE2\n2025-10-01\n2031-06\n154\n2025-10-01\n\n\nNCT04305041\nMerck Sharp & Dohme LLC\nğŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-08-25\n100\n2025-08-28\n\n\nNCT04543617\nHoffmann-La Roche\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2020-09-28\n2027-03-31\n760\n2026-01-16\n\n\nNCT05676931\nGilead Sciences\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Non-Small Cell Lung Cancer\nPHASE2\n2023-02-21\n2027-12\n400\n2025-09-29\n\n\nNCT06996782\nAstraZeneca\nğŸŸ¢ No Change\nRECRUITING\nAdvanced or Metastatic Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2025-11-24\n2029-02-23\n152\n2026-01-13\n\n\nNCT05665595\nMerck Sharp & Dohme LLC\nğŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE3\n2023-01-19\n2025-09-26\n1594\n2025-10-03\n\n\nNCT06868277\nAstraZeneca\nğŸŸ¢ No Change\nRECRUITING\nCarcinoma, Non-Small Cell Lung\nPHASE3\n2025-04-10\n2030-12-02\n830\n2026-01-12\n\n\nNCT04774484\nFrancesc Marti\nğŸŸ¢ No Change\nWITHDRAWN\nEnd Stage Renal Disease\nNA\n2023-01\n2026-06-30\n0\n2023-02-10\n\n\nNCT06692738\nAstraZeneca\nğŸŸ¢ No Change\nRECRUITING\nNon-small Cell Lung Cancer\nPHASE3\n2024-11-18\n2029-10-08\n880\n2026-01-20\n\n\nNCT04256421\nHoffmann-La Roche\nğŸŸ¢ No Change\nCOMPLETED\nSmall Cell Lung Cancer\nPHASE3\n2020-02-04\n2025-07-31\n490\n2026-01-09\n\n\nNCT05816460\nUniversity College Dublin\nğŸŸ¢ No Change\nUNKNOWN\nInsomnia, Cancer\nNA\n2023-05-22\n2024-06-10\n308\n2023-05-19\n\n\nNCT04305054\nMerck Sharp & Dohme LLC\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1, PHASE2\n2020-07-01\n2026-04-20\n315\n2025-08-28\n\n\nNCT06989112\nAstraZeneca\nğŸ”´ Changed\nRECRUITING\nEndometrial Cancer\nPHASE3\n2025-03-27\n2031-02-19\n600\n2026-02-09\n\n\nNCT06627647\nAstraZeneca\nğŸ”´ Changed\nRECRUITING\nNon-squamous Non-small Cell Lung Cancer\nPHASE3\n2024-11-27\n2030-03-25\n878\n2026-02-11\n\n\nNCT03198546\nSecond Affiliated Hospital of Guangzhou Medical University\nğŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT04294810\nHoffmann-La Roche\nğŸŸ¢ No Change\nCOMPLETED\nNon-Small Cell Lung Cancer\nPHASE3\n2020-03-04\n2025-12-30\n620\n2026-01-29\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nğŸŸ¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT04585815\nPfizer\nğŸŸ¢ No Change\nTERMINATED\nCarcinoma, Non-Small-Cell Lung\nPHASE1, PHASE2\n2020-11-10\n2024-10-29\n34\n2025-12-18\n\n\nNCT02443155\nNovo Nordisk A/S\nğŸŸ¢ No Change\nCOMPLETED\nDiabetes, Diabetes Mellitus, Type 1\nPHASE2\n2015-11-10\n2019-02-27\n308\n2021-03-10"
  },
  {
    "objectID": "targets/ige.html",
    "href": "targets/ige.html",
    "title": "IgE",
    "section": "",
    "text": "Note\n\n\n\nIgE íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§"
  },
  {
    "objectID": "targets/ige.html#visual-summary",
    "href": "targets/ige.html#visual-summary",
    "title": "IgE",
    "section": "Visual Summary",
    "text": "Visual Summary\n\nStatus & PhaseTop Sponsors"
  },
  {
    "objectID": "targets/ige.html#change-history",
    "href": "targets/ige.html#change-history",
    "title": "IgE",
    "section": "Change History",
    "text": "Change History\n\nTarget MilestonesTrial Changes\n\n\nDate: 2026-02-05 15:28:42\nInitial data collection: 267 trials found.\n\n\n\nNo specific trial changes (beyond initial collection) recorded yet for ige.\n\n\n\n\nğŸ“¥ Download Full Data (CSV) ğŸ“¥ Download Status Summary (CSV)"
  },
  {
    "objectID": "targets/ige.html#monitoring-status",
    "href": "targets/ige.html#monitoring-status",
    "title": "IgE",
    "section": "Monitoring Status",
    "text": "Monitoring Status\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT02546921\nCancer Research UK\nğŸŸ¢ No Change\nCOMPLETED\nHuman Cancers\nPHASE1\n2016-02-16\n2021-07-30\n26\n2022-07-15\n\n\nNCT06547840\nEpsilogen Ltd\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Ovarian Cancer, Platinum-resistant Ovarian Cancer\nPHASE1\n2024-09-03\n2027-03\n45\n2025-06-18\n\n\nNCT03019237\nMedical University of Vienna\nğŸŸ¢ No Change\nCOMPLETED\nAllergy\nNA\n2012-11\n2013-05\n15\n2017-01-10"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "ì„ìƒì‹œí—˜ì„ íƒ€ê²Ÿë³„ë¡œ ëª¨ë‹ˆí„°ë§í•©ë‹ˆë‹¤.\n\n\n\nTarget\nDescription\nTrials\nChanged\n\n\n\n\nCCR8\nCCR8 íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§\n32\nğŸ”´ 3\n\n\nTIGIT\nTIGIT íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§\n133\nğŸ”´ 8\n\n\nIgE\nê·¸ëƒ¥ í…ŒìŠ¤íŠ¸ìš©\n3\nğŸŸ¢ 0\n\n\nB7-H3\nB7-H3 íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§\n111\nğŸ”´ 2"
  },
  {
    "objectID": "index.html#targets-overview",
    "href": "index.html#targets-overview",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "ì„ìƒì‹œí—˜ì„ íƒ€ê²Ÿë³„ë¡œ ëª¨ë‹ˆí„°ë§í•©ë‹ˆë‹¤.\n\n\n\nTarget\nDescription\nTrials\nChanged\n\n\n\n\nCCR8\nCCR8 íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§\n32\nğŸ”´ 3\n\n\nTIGIT\nTIGIT íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§\n133\nğŸ”´ 8\n\n\nIgE\nê·¸ëƒ¥ í…ŒìŠ¤íŠ¸ìš©\n3\nğŸŸ¢ 0\n\n\nB7-H3\nB7-H3 íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§\n111\nğŸ”´ 2"
  },
  {
    "objectID": "targets/b7-h3.html",
    "href": "targets/b7-h3.html",
    "title": "B7-H3",
    "section": "",
    "text": "Note\n\n\n\nB7-H3 íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§"
  },
  {
    "objectID": "targets/b7-h3.html#visual-summary",
    "href": "targets/b7-h3.html#visual-summary",
    "title": "B7-H3",
    "section": "Visual Summary",
    "text": "Visual Summary\n\nStatus & PhaseTop Sponsors"
  },
  {
    "objectID": "targets/b7-h3.html#change-history",
    "href": "targets/b7-h3.html#change-history",
    "title": "B7-H3",
    "section": "Change History",
    "text": "Change History\n\nTarget MilestonesTrial Changes\n\n\nDate: 2026-02-16 21:11:23\nChanges detected in 2 trials: NCT06330064, NCT04514484\n\nDate: 2026-02-12 14:14:38\nChanges detected in 4 trials: NCT06892548, NCT06780137, NCT07386002, NCT04514484\n\nDate: 2026-02-10 07:04:06\nChanges detected in 9 trials: NCT07222735, NCT06646627, NCT06203210, NCT06242470, NCT07386002, NCT06362252, NCT06953089, NCT04514484, NCT04743661\n\nDate: 2026-02-05 17:03:12\nInitial data collection: 111 trials found.\n\n\n\n\nNCT07222735\nDate: 2026-02-10 07:03:56\nField statusModule.statusVerifiedDate changed from 2025-11 to 2026-02 Field statusModule.startDateStruct.date changed from 2025-12-05 to 2026-01-21 Field statusModule.startDateStruct.type changed from ESTIMATED to ACTUAL Field statusModule.lastUpdateSubmitDate changed from 2025-11-18 to 2026-02-06 Field statusModule.lastUpdatePostDateStruct.date changed from 2025-11-19 to 2026-02-09\n\n\n\nNCT06646627\nDate: 2026-02-10 07:03:56\nField statusModule.statusVerifiedDate changed from 2025-07 to 2026-02 Field statusModule.primaryCompletionDateStruct.date changed from 2025-12 to 2026-07 Field statusModule.completionDateStruct.date changed from 2025-12 to 2026-07 Field statusModule.lastUpdateSubmitDate changed from 2025-07-07 to 2026-02-05 Field statusModule.lastUpdatePostDateStruct.date changed from 2025-07-10 to 2026-02-09\n\n\n\n\n\n\nğŸ“¥ Download Full Data (CSV) ğŸ“¥ Download Status Summary (CSV)"
  },
  {
    "objectID": "targets/b7-h3.html#monitoring-status",
    "href": "targets/b7-h3.html#monitoring-status",
    "title": "B7-H3",
    "section": "Monitoring Status",
    "text": "Monitoring Status\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04385173\nSecond Affiliated Hospital, School of Medicine, Zhejiang University\nğŸŸ¢ No Change\nUNKNOWN\nRecurrent Glioblastoma, Refractory Glioblastoma\nPHASE1\n2022-12-01\n2024-05-01\n12\n2022-12-25\n\n\nNCT06500819\nCrystal Mackall, MD\nğŸŸ¢ No Change\nRECRUITING\nNeuroblastoma, Sarcoma, Osteosarcoma\nPHASE1\n2024-07-11\n2029-07\n41\n2025-04-18\n\n\nNCT06778603\nPeking University Peopleâ€™s Hospital\nğŸŸ¢ No Change\nRECRUITING\nOsteosarcoma, Resection Margins, B7-H3 Probe, Local Recurrence\nPHASE1, PHASE2\n2024-01-01\n2026-12-31\n32\n2025-01-11\n\n\nNCT04897321\nSt.Â Jude Childrenâ€™s Research Hospital\nğŸŸ¢ No Change\nRECRUITING\nPediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma\nPHASE1\n2022-07-06\n2027-03-01\n32\n2025-10-23\n\n\nNCT04077866\nSecond Affiliated Hospital, School of Medicine, Zhejiang University\nğŸŸ¢ No Change\nUNKNOWN\nRecurrent Glioblastoma, Refractory Glioblastoma\nPHASE1, PHASE2\n2023-06-01\n2025-08-01\n40\n2022-12-25\n\n\nNCT06158139\nUNC Lineberger Comprehensive Cancer Center\nğŸŸ¢ No Change\nRECRUITING\nPancreas Cancer, Relapse, Resistant Cancer\nPHASE1\n2024-07-18\n2028-06\n27\n2025-03-14\n\n\nNCT05942456\nPeking University Peopleâ€™s Hospital\nğŸŸ¢ No Change\nRECRUITING\nBiomarker, Progression, Osteosarcoma, Surveillance\nN/A\n2023-06-05\n2024-12-31\n200\n2024-05-11\n\n\nNCT05474378\nStanford University\nğŸŸ¢ No Change\nRECRUITING\nBrain and Nervous System\nPHASE1\n2022-07-12\n2026-08\n39\n2025-10-10\n\n\nNCT02982941\nMacroGenics\nğŸŸ¢ No Change\nCOMPLETED\nNeuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor\nPHASE1\n2016-12\n2019-05-22\n25\n2022-02-04\n\n\nNCT04432649\nShenzhen Geno-Immune Medical Institute\nğŸŸ¢ No Change\nUNKNOWN\nSolid Tumor\nPHASE1, PHASE2\n2020-06-01\n2024-05-31\n100\n2020-06-11\n\n\nNCT06018363\nDushu Lake Hospital Affiliated to Soochow University\nğŸŸ¢ No Change\nRECRUITING\nBrain Gliomas, High-Grade Gliomas, GBM\nPHASE1, PHASE2\n2023-06-01\n2027-12-31\n25\n2025-08-13\n\n\nNCT05835687\nSt.Â Jude Childrenâ€™s Research Hospital\nğŸŸ¢ No Change\nRECRUITING\nCentral Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, High Grade Glioma, Glioblastoma, Medulloblastoma\nPHASE1\n2023-04-27\n2028-03\n48\n2026-01-15\n\n\nNCT06347068\nUNC Lineberger Comprehensive Cancer Center\nğŸŸ¢ No Change\nRECRUITING\nBreast Cancer, Relapse, Resistant Cancer, Triple Negative Breast Cancer\nPHASE1\n2024-06-27\n2028-05\n42\n2025-09-15\n\n\nNCT07222735\nSt.Â Jude Childrenâ€™s Research Hospital\nğŸ”´ Changed\nRECRUITING\nSarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma\nPHASE1\n2026-01-21\n2031-11-05\n42\n2026-02-06\n\n\nNCT06646627\nStanford University\nğŸ”´ Changed\nRECRUITING\nOvarian Cancer\nPHASE1\n2024-11-11\n2026-07\n48\n2026-02-05\n\n\nNCT05515185\nThe First Peopleâ€™s Hospital of Lianyungang\nğŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nEARLY_PHASE1\n2022-09-09\n2024-09-08\n30\n2022-08-23\n\n\nNCT02628535\nMacroGenics\nğŸŸ¢ No Change\nTERMINATED\nMesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma\nPHASE1\n2015-09\n2019-11-25\n67\n2022-02-04\n\n\nNCT07358260\nRobbie Majzner\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nPediatric Solid Tumor, Neuroblastoma\nPHASE1\n2026-06\n2031-12-31\n40\n2026-01-14\n\n\nNCT05562024\nPersonGen BioTherapeutics (Suzhou) Co., Ltd.\nğŸŸ¢ No Change\nRECRUITING\nB7-H3-positive Relapsed/ Refractory Neuroblastoma\nPHASE1\n2022-12-30\n2039-02-18\n24\n2023-02-23\n\n\nNCT05241392\nBeijing Tiantan Hospital\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nPHASE1\n2022-01-27\n2026-12-31\n30\n2025-02-09\n\n\nNCT04670068\nUNC Lineberger Comprehensive Cancer Center\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nEpithelial Ovarian Cancer\nPHASE1\n2021-01-27\n2030-02\n4\n2025-12-04\n\n\nNCT05366179\nUNC Lineberger Comprehensive Cancer Center\nğŸŸ¢ No Change\nRECRUITING\nGlioblastoma Multiforme\nPHASE1\n2022-09-02\n2030-05-30\n36\n2025-10-16\n\n\nNCT03406949\nMacroGenics\nğŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumors\nPHASE1\n2018-02-27\n2022-04-27\n25\n2022-05-18\n\n\nNCT07172958\nChildrenâ€™s National Research Institute\nğŸŸ¢ No Change\nRECRUITING\nRhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma, Wilms Tumor\nPHASE1\n2026-01-27\n2038-12\n18\n2026-01-26\n\n\nNCT06454955\nPeking University Cancer Hospital & Institute\nğŸŸ¢ No Change\nRECRUITING\nB7H3, CD276 Affibody, PET/CT Imaing\nEARLY_PHASE1\n2024-01-01\n2026-11-30\n50\n2024-08-21\n\n\nNCT05752877\nSecond Affiliated Hospital of Soochow University\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy\nNA\n2021-05-01\n2026-04-30\n12\n2023-03-02\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nğŸŸ¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT05190185\nPersonGen BioTherapeutics (Suzhou) Co., Ltd.\nğŸŸ¢ No Change\nUNKNOWN\nMalignant Melanoma, Lung Cancer, or Colorectal Cancer\nPHASE1\n2021-06-01\n2023-12-01\n18\n2021-12-29\n\n\nNCT06951243\nBeijing GoBroad Hospital\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nAdvanced Extrapulmonary Neuroendocrine Cancer\nPHASE2\n2025-05-06\n2028-05-06\n40\n2025-04-22\n\n\nNCT06305299\nUNC Lineberger Comprehensive Cancer Center\nğŸŸ¢ No Change\nRECRUITING\nOvary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent\nPHASE1\n2024-07-29\n2026-03\n27\n2025-09-12\n\n\nNCT07189871\nRadiopharm Theranostics, Ltd\nğŸŸ¢ No Change\nRECRUITING\nCastration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)\nPHASE1, PHASE2\n2026-02\n2027-12\n61\n2026-01-13\n\n\nNCT05731219\nPersonGen BioTherapeutics (Suzhou) Co., Ltd.\nğŸŸ¢ No Change\nUNKNOWN\nRelapsed/Refractory Acute Myeloid Leukemia\nPHASE1\n2022-09-26\n2025-09-26\n18\n2023-02-15"
  },
  {
    "objectID": "targets/ccr8.html",
    "href": "targets/ccr8.html",
    "title": "CCR8",
    "section": "",
    "text": "Note\n\n\n\nCCR8 íƒ€ê²Ÿ ì„ìƒì‹œí—˜ ëª¨ë‹ˆí„°ë§"
  },
  {
    "objectID": "targets/ccr8.html#visual-summary",
    "href": "targets/ccr8.html#visual-summary",
    "title": "CCR8",
    "section": "Visual Summary",
    "text": "Visual Summary\n\nStatus & PhaseTop Sponsors"
  },
  {
    "objectID": "targets/ccr8.html#change-history",
    "href": "targets/ccr8.html#change-history",
    "title": "CCR8",
    "section": "Change History",
    "text": "Change History\n\nTarget MilestonesTrial Changes\n\n\nDate: 2026-02-12 14:01:36\nChanges detected in 1 trials: NCT05537740\n\nDate: 2026-02-10 07:03:39\nChanges detected in 2 trials: NCT07205718, NCT06657144\n\nDate: 2026-02-05 15:26:51\nInitial data collection: 12 trials found.\n\n\n\n\nNCT07205718\nDate: 2026-02-10 07:03:39\nField statusModule.statusVerifiedDate changed from 2025-11 to 2026-02 Field statusModule.lastUpdateSubmitDate changed from 2025-11-28 to 2026-02-04 Field statusModule.lastUpdatePostDateStruct.date changed from 2025-12-01 to 2026-02-06 Field contactsLocationsModule.locations.[2]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[4]status changed from NOT_YET_RECRUITING to RECRUITING Field contactsLocationsModule.locations.[10]status changed from NOT_YET_RECRUITING to RECRUITING\n\n\n\nNCT06657144\nDate: 2026-02-10 07:03:39\nField statusModule.statusVerifiedDate changed from 2026-01 to 2026-02 Field statusModule.lastUpdateSubmitDate changed from 2026-01-12 to 2026-02-03 Field statusModule.lastUpdatePostDateStruct.date changed from 2026-01-13 to 2026-02-05\n\n\n\nNCT05537740\nDate: 2026-02-12 14:01:36\nField removed: root['referencesModule']['seeAlsoLinks']\n\n\n\n\n\n\nğŸ“¥ Download Full Data (CSV) ğŸ“¥ Download Status Summary (CSV)"
  },
  {
    "objectID": "targets/ccr8.html#monitoring-status",
    "href": "targets/ccr8.html#monitoring-status",
    "title": "CCR8",
    "section": "Monitoring Status",
    "text": "Monitoring Status\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT05255484\nLaNova Medicines Limited\nğŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1, PHASE2\n2022-05-26\n2023-10-06\n24\n2023-10-24\n\n\nNCT06821503\nChia Tai Tianqing Pharmaceutical Group Co., Ltd.\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nAdvanced Pancreatic Cancer\nPHASE1, PHASE2\n2025-02\n2028-12\n72\n2025-02-13\n\n\nNCT05859464\nZai Lab (Hong Kong), Ltd.\nğŸŸ¢ No Change\nTERMINATED\nMalignant Solid Tumor\nPHASE1\n2023-07-24\n2025-08-28\n34\n2025-10-14\n\n\nNCT05199753\nLaNova Australia Pty Limited\nğŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumor\nPHASE1, PHASE2\n2022-03-16\n2024-12-31\n78\n2025-09-06\n\n\nNCT06479759\nShanghai Pulmonary Hospital, Shanghai, China\nğŸŸ¢ No Change\nRECRUITING\nNSCLC, PD-1\nPHASE2\n2024-01-12\n2025-12-12\n50\n2024-06-24\n\n\nNCT05518045\nLaNova Medicines Limited\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Solid Tumor\nPHASE1, PHASE2\n2022-08-26\n2026-03-31\n392\n2026-02-01\n\n\nNCT04895709\nBristol-Myers Squibb\nğŸŸ¢ No Change\nRECRUITING\nCervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms\nPHASE1, PHASE2\n2021-05-27\n2028-07-07\n949\n2025-12-16\n\n\nNCT06825494\nChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor\nPHASE1, PHASE2\n2025-04-08\n2026-09\n194\n2025-12-10\n\n\nNCT05005403\nAbbVie\nğŸŸ¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer\nPHASE1\n2021-11-01\n2027-06\n512\n2025-10-27\n\n\nNCT06873854\nLaNova Medicines Limited\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nAdvanced Solid Tumor\nPHASE2\n2025-03-26\n2030-01-26\n84\n2025-03-10\n\n\nNCT05690581\nBeijing InnoCare Pharma Tech Co., Ltd.\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors and Hematologic Malignancies\nPHASE1\n2023-02-23\n2026-02-28\n146\n2024-12-22\n\n\nNCT05581004\nGenentech, Inc.\nğŸŸ¢ No Change\nRECRUITING\nLocally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC\nPHASE1\n2022-10-20\n2027-02-28\n450\n2026-01-16\n\n\nNCT06131398\nAmgen\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Solid Tumors\nPHASE1\n2024-03-07\n2026-08-03\n77\n2025-12-19\n\n\nNCT06911827\nQilu Pharmaceutical Co., Ltd.\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nAdvanced Solid Tumor\nPHASE1, PHASE2\n2025-04\n2028-12\n90\n2025-04-07\n\n\nNCT06819735\nDomain Therapeutics Australia Pty Ltd\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1, PHASE2\n2025-06-25\n2028-01\n125\n2025-11-14\n\n\nNCT07011550\nM.D.Â Anderson Cancer Center\nğŸŸ¢ No Change\nRECRUITING\nMicrosatellite-stable Colorectal Cancer, Standard of Care, Nivolumab, Bevacizumab\nPHASE2\n2025-11-30\n2030-07-01\n40\n2025-08-20\n\n\nNCT06963814\nHC Biopharma Inc.\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Cancer\nPHASE1\n2025-07-04\n2027-05-30\n252\n2025-07-14\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT06304571\nHC Biopharma Inc.\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor\nPHASE1\n2024-02-27\n2026-07-16\n76\n2025-04-30\n\n\nNCT05830045\nQilu Pharmaceutical Co., Ltd.\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2023-05-19\n2025-12-31\n180\n2024-06-25\n\n\nNCT07362186\nLaNova Medicines Limited\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nLocally Advanced or Metastatic GC and GCJ Adenocarcinoma\nPHASE3\n2026-04-03\n2028-09-28\n400\n2026-01-15\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT07205718\nTakeda\nğŸ”´ Changed\nRECRUITING\nAdvanced or Metastatic Solid Tumors\nPHASE1, PHASE2\n2025-11-19\n2029-12-21\n223\n2026-02-04\n\n\nNCT05007782\nGilead Sciences\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor\nPHASE1\n2021-08-18\n2028-12\n416\n2025-12-26\n\n\nNCT05101070\nShionogi\nğŸŸ¢ No Change\nRECRUITING\nSolid Tumors\nPHASE1, PHASE2\n2022-05-30\n2027-04-16\n274\n2025-05-22\n\n\nNCT06657144\nCoherus Oncology, Inc.\nğŸ”´ Changed\nRECRUITING\nMetastatic Solid Tumor, Advanced Solid Tumor\nPHASE1\n2025-04-01\n2027-05\n154\n2026-02-03\n\n\nNCT06387628\nFudan University\nğŸŸ¢ No Change\nRECRUITING\nTNBC - Triple-Negative Breast Cancer\nPHASE2\n2024-07-10\n2027-04-01\n74\n2024-08-01\n\n\nNCT05935098\nBeiGene\nğŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor\nPHASE1\n2023-08-21\n2027-03-31\n263\n2025-06-23\n\n\nNCT05635643\nCoherus Oncology, Inc.\nğŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor, Head and Neck Squamous Cell Carcinoma\nPHASE1\n2022-12-15\n2026-02\n87\n2025-07-30\n\n\nNCT05537740\nBayer\nğŸ”´ Changed\nACTIVE_NOT_RECRUITING\nAdvanced Solid Tumors\nPHASE1\n2022-10-11\n2027-05-04\n129\n2026-01-21\n\n\nNCT06620822\nShanghai Pulmonary Hospital, Shanghai, China\nğŸŸ¢ No Change\nNOT_YET_RECRUITING\nNon Small Cell Lung Cancer\nPHASE2\n2024-09-30\n2027-09-30\n296\n2024-09-28\n\n\nNCT07226856\nMayo Clinic\nğŸŸ¢ No Change\nRECRUITING\nMetastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8\nPHASE2\n2025-12-12\n2028-12-01\n43\n2025-12-19"
  }
]